37067-27-9

Basic information

• Product Name: HYDROQUINONE MONOSULFATE POTASSIUM SALT
• Synonyms: HYDROQUINONE MONOSULFATE POTASSIUM SALT;POTASSIUM HYDROQUINONE MONOSULFATE;potassium p-hydroxyphenyl sulphate;Hydroquinone sulfate potassium;Sulfuric acid 4-hydroxyphenyl=potassium salt;Sulfuric acid potassium 4-hydroxyphenyl ester salt;Potassium 4-hydroxyphenyl sulfate
• CAS NO: 37067-27-9
• Molecular Formula: C₆H₅O₅S*K
• Molecular Weight: 228.26
• EINECS: 253-332-5
• Mol File: 37067-27-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• CAS DataBase Reference: HYDROQUINONE MONOSULFATE POTASSIUM SALT(CAS DataBase Reference)
• NIST Chemistry Reference: HYDROQUINONE MONOSULFATE POTASSIUM SALT(37067-27-9)
• EPA Substance Registry System: HYDROQUINONE MONOSULFATE POTASSIUM SALT(37067-27-9)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 37067-27-9(Hazardous Substances Data)

Usage

Description

Hydroquinone monosulfate potassium salt is a chemical compound characterized by its reducing agent properties, containing one sulfate group and a potassium ion. It plays a crucial role in facilitating various chemical reactions across different industries, including cosmetics, pharmaceuticals, and manufacturing.

Uses

Used in Cosmetic Industry:
Hydroquinone monosulfate potassium salt is used as a skin lightening agent for its ability to inhibit the production of melanin, the pigment responsible for skin color. This application is particularly beneficial for treating hyperpigmentation and uneven skin tone.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, hydroquinone monosulfate potassium salt serves as an intermediate in the synthesis of various drugs. Its reducing properties make it a valuable component in the production of medications that require specific chemical reactions for their formation.
Used in Manufacturing Industry:
Hydroquinone monosulfate potassium salt is utilized as a chemical intermediate in the manufacturing of various products. Its ability to facilitate chemical reactions is essential in the production process, ensuring the successful synthesis of desired compounds.

InChI:InChI=1/C6H6O5S.K/c7-5-1-3-6(4-2-5)11-12(8,9)10;/h1-4,7H,(H,8,9,10);/q;+1/p-1

Upstream product

• 123-31-9 hydroquinone 
• 108-95-2 phenol 

Downstream Products

• 65343-67-1 ethyl 2-(4-hydroxyphenoxy)propanoate 
• 20872-28-0 ethyl 2-(4-hydroxyphenoxy)acetate 
• 81947-94-6 n-butyl 2-(4-hydroxyphenoxy)propionate 
• 94050-90-5 (RS)-2-(4-hydroxyphenoxy)propionic acid 
• 70067-75-3 methyl 2-(4-hydroxyphenoxy)acetate 
• 1878-84-8 (4-hydroxyphenoxy)acetic acid 

Relevant articles and documents

-

-

Urinary excretion of arbutin metabolites after oral administration of bearberry leaf extracts

An HPLC assay with fluorimetric detection of the arbutin metabolites hydroquinone glucuronide (2) and hydroquinone sulphate (6) in urine was developed and validated. Methylarbutin (4) and 6 were synthesised as reference substances. Compound 2 was prepared enzymatically from hydroquinone and uridine 5-diphosphoglucuronic acid using the glucosyltransferase system of rat liver microsomes and enriched by two liquid-liquid and an additional solid phase extraction. Compound 2 as the main component of this purified product was identified by UV and fluorescence spectroscopy, by HPLC-MS, and by enzymatic hydrolysis to hydroquinone (5). The assay yields precise and accurate urine levels of 2, 5 and 6 in the concentration range expected after oral administration of recommended therapeutic doses of bearberry leaf extract. In a preliminary pharmacokinetic study on 3 volunteers the time-dependent renal excretion of arbutin metabolites 2, 5 and 6 was investigated after ingestion of an aqueous bearberry leaf extract containing an arbutin dose recommended by the German Kommission E. More than half of the administered dose of arbutin was excreted within 4 hours mainly in form of the metabolites 2 and 6 and more than 75% of the total applied arbutin was excreted within 24 h. The elimination of 5 was negligible in 2 out of 3 volunteers. The excretion of this metabolite in the third test person reached 5.6% of the total administered arbutin dose. The preliminary pharmacokinetic results confirm that renal elimination of toxicologically critical concentrations of the metabolite 5 will not be expected.

Process for the synthesis of phenoxyalkane derivatives

The invention concerns a process for the synthesis of a compound of formula I STR1 wherein: U and V may be chosen from a range of substituents including hydrogen, halogen, alkyl and alkoxy; R1 and R2 may be chosen from a range of substituents including hydrogen and alkyl; n is 0, 1 or 2; and W may be chosen from a range of substitutents including the group STR2 which may be a free carboxylic acid or derivative thereof; the process comprising reacting a sulfate ester of formula II, wherein Q is a cation, with a compound of formula III, wherein L is a leaving group STR3 and hydrolyzing the sulfate ester formed. Preferably the sulfate ester of formula II is prepared by the oxidation of a phenol of formula IV with a persulfate. STR4